$name

Back

SANTA MONICA, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will present a company overview at three upcoming investor conferences in May 2015:

Credit Suisse Antibody DayWednesday, May 6, 2015, at 8:00am Local TimeCredit Suisse Offices, New York, New York
Bank of America Merrill Lynch 2015 Health Care ConferenceTuesday, May 12, 2015,at 1:40pm Local TimeEncore at the Wynn, Las Vegas, Nevada
UBS Global Healthcare ConferenceTuesday, May 19, 2015, at 8:30am Local TimeSheraton New York Times Square Hotel, New York, New York

The Company's corporate overview to be presented at the Credit Suisse Antibody Day will be available through the Calendar of Events section of the Company's website at ir.kitepharma.com.

Dr. Chang will also participate in the CAR-T Panel as part of the Piper Jaffray GenomeRx Symposium on Wednesday, May 20, 2015, at 10:25am Local Time at The New York Palace Hotel, New York, New York.

About Kite Pharma

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA.

CONTACT: Kite PharmaCynthia M. Butitta

         Chief Financial Officer and Chief Operating Officer

         310-824-9999



         For Media: Justin Jackson

         For Investor Inquiries: Lisa Burns and Carol WertherBurns McClellan

         212-213-0006

         jackson@burnsmc.comburns@burnsmc.comcwerther@burnsmc.com

Kite Pharma, Inc.

News Provided by Acquire Media